StageSeries A | Alive
Last Raised$50M | 1 yr ago
Missing: Cimeio Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cimeio Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Cimeio Therapeutics News
May 16, 2023
CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD45 Shielded Cell & Immunotherapy Pair (SCIP) program at the American Society of Gene and Cell Therapy’s Annual Meeting in Los Angeles. The findings build upon prior successful studies using CD117 and CD123 variants and collectively provide further proof of concept for Cimeio’s platform, which offers a novel and promising
Cimeio Therapeutics Frequently Asked Questions (FAQ)
When was Cimeio Therapeutics founded?
Cimeio Therapeutics was founded in 2020.
Where is Cimeio Therapeutics's headquarters?
Cimeio Therapeutics's headquarters is located at Aeschenvorstadt 36, Basel.
What is Cimeio Therapeutics's latest funding round?
Cimeio Therapeutics's latest funding round is Series A.
How much did Cimeio Therapeutics raise?
Cimeio Therapeutics raised a total of $50M.
Who are the investors of Cimeio Therapeutics?
Investors of Cimeio Therapeutics include Versant Ventures.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.